Quantcast

Latest National Institute for Health and Clinical Excellence Stories

2008-08-09 06:00:22

By Barry Nelson A CANCER patient who has survived in the past year because of a wonder drug has condemned plans to deny it to other patients because of the cost. Stan Craddock, 63, from Darlington, said he survived the past ten months because of the drug Sutent. Last night, he said he could not believe that such a powerful cancer drug was effectively going to be banned by the NHS. This followed the draft guidance from the National Institute for Health and Clinical Excellence (Nice)...

2008-08-08 00:00:39

Britain's National Health Service said it rejected four new drugs designed to treat advanced kidney cancer because the cost is too high. The National Institute for Health and Clinical Excellence said the drugs -- Sutent (sunitinib), Avastin (bevacizumab), Nexavar (sorafenib) and Torisel (temsirolimus) -- are too expensive and the money can be better put to other use, the Times of London said Thursday. The newspaper said cancer organizations are outraged by the decision. Advocates for the...

2008-08-08 00:00:11

By Ian Johnston CAMPAIGNERS EXPRESSED outrage yesterday at a decision to deny four drug treatments to NHS patients with advanced kidney cancer. The National Institute for Health and Clinical Excellence (Nice) issued draft guidance rejecting the drugs Sutent (sunitinib), Avastin (bevacizumab), Nexavar (sorafenib) and Torisel (temsirolimus). This leaves patients with only one treatment option - interferon. Professor John Wagstaff, from the South Wales Cancer Institute, said there was "no...

2008-08-08 00:00:11

By JEREMY LAURANCE The big question Why are we asking this now? CANCER CHARITIES, kidney specialists and campaigners were outraged yesterday when the National Institute for Clinical Excellence (Nice), announced that it had rejected four new drugs for advanced kidney cancer as too expensive for the NHS. In draft guidance, the medicines watchdog said that the drugs can extend life by five to six months on average but they cost too much. The money would do more good if it were spent...

2008-08-07 18:01:52

PATIENTS with advanced kidney cancer will be denied four treatments on the NHS under new guidelines. The National Institute for Health and Clinical Excellence (Nice) issued draft guidance rejecting the drugs. Charities expressed outrage at the decision. (c) 2008 Liverpool Echo. Provided by ProQuest Information and Learning. All rights Reserved.

2008-08-07 18:00:00

By JANE KIRBY PATIENTS with advanced kidney cancer will be denied four treatments on the NHS under new guidelines published yesterday. The National Institute for Health and Clinical Excellence (Nice) issued draft guidance rejecting the drugs Sutent (sunitinib), Avastin (bevacizumab), Nexavar (sorafenib) and Torisel (temsirolimus). Primary care trusts in Merseyside and Cheshire had already agreed to start offering Sutent on the NHS, as reported by the Daily Post in December last year....

2008-08-07 18:00:00

By Greg Tindle A WELSH cancer expert has described as "an outrage" plans to deny patients with advanced kidney cancer four types of drug treatment on the NHS. Under new guidelines the National Institute for Health and Clinical Excellence (Nice) - the Government's medicines watchdog - has turned down the use of the drugs saying they are not cost effective. Charities have expressed concern at the decision, saying it has left patients only one treatment option - interferon - to which...

2008-08-07 18:00:23

By Emma Brady Midland cancer experts have hit out at a decision to deny kidney cancer patients four drugs under new NHS guidelines issued yesterday. The National Institute for Health and Clinical Excellence (Nice) issued draft guidance rejecting the drugs Sutent (sunitinib), Avastin (bevacizumab), Nexavar (sorafenib) and Torisel (temsirolimus) which cost between pounds 20,000 and pounds 35,000 per patient per year. This leaves just one cancer drug, interferon, to which many patients...

2008-08-07 18:00:00

By HELEN RAE PATIENTS with advanced kidney cancer will be denied four life- extending treatments on the NHS because they are not cost effective. The National Institute for Health and Clinical Excellence (Nice) yesterday issued draft guidance rejecting the drugs Sutent (Sunitinib), Avastin, Nexavar and Torisel. Charities expressed outrage at the decision, saying it left patients only one treatment option - Interferon - to which many do not respond. Cancer sufferer Ken Potts, 55, of...

2008-08-07 15:00:12

By HELEN PUTTICK HEALTH CORRESPONDENT CHARITIES yesterday spoke out about the NHS refusing patients new treatments for a rare form of cancer. Drugs watchdog for England and Wales, the National Institute for Health and Clinical Excellence (Nice), has ruled four new kidney cancer medicines are effective but do not offer the health service good value for money. In Scotland, equivalent body the Scottish Medicines Consortium (SMC), has already rejected three of the treatments. Cancer...


Word of the Day
penuche
  • A fudgelike confection of brown sugar, cream or milk, and chopped nuts.
'Penuche' is a variant of 'panocha,' a coarse grade of sugar made in Mexico. 'Panocha' probably comes from the Spanish 'panoja, panocha,' ear of grain.
Related